Thyroid-stimulating hormone levels in the normal range and incident type 2 diabetes mellitus.


Journal

Acta diabetologica
ISSN: 1432-5233
Titre abrégé: Acta Diabetol
Pays: Germany
ID NLM: 9200299

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 20 07 2018
accepted: 17 09 2018
pubmed: 28 9 2018
medline: 6 5 2019
entrez: 28 9 2018
Statut: ppublish

Résumé

To evaluate the relationship between thyroid-stimulating hormone (TSH) levels within the normal range and the risk of type 2 diabetes mellitus (T2DM) in a cohort of patients at high cardiovascular risk, and to perform a systematic review and meta-analysis of previous studies. We included 5542 patients without T2DM from the prospective Secondary Manifestations of ARTerial disease study with TSH levels between 0.35 and 5.0 mIU/L without anti-thyroid medication or thyroid-hormone replacement therapy. Cox regression was used to investigate the relationship between baseline plasma TSH levels and incident T2DM. MEDLINE, EMBASE, and Cochrane were searched for prospective cohorts assessing TSH and incident T2DM. Hazard ratios (HR) from included prospective cohort studies were pooled using a random-effects model. In patients at high cardiovascular risk, higher plasma TSH levels in the normal range were not associated [HR 1.07 per mIU/L increase in TSH (95% confidence interval (95% CI) 0.95-1.22)] with an increased risk of T2DM, adjusted for age, sex, smoking, total and HDL cholesterol, and triglycerides. In the meta-analysis involving three prospective cohort studies, including the present study, including 29,791 participants with 1930 incident events, there was no relation between plasma TSH levels in the normal range and incident T2DM [pooled HR 1.06 (95% CI 0.99-1.14)]. There is no apparent relation between plasma TSH levels in the normal range and incident T2DM in patients at high cardiovascular risk.

Identifiants

pubmed: 30259116
doi: 10.1007/s00592-018-1231-y
pii: 10.1007/s00592-018-1231-y
pmc: PMC6420678
doi:

Substances chimiques

Thyrotropin 9002-71-5

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

431-440

Références

Eur J Epidemiol. 1999 Oct;15(9):773-81
pubmed: 10608355
Stat Med. 2001 Mar 30;20(6):825-40
pubmed: 11252006
J Clin Endocrinol Metab. 2002 Feb;87(2):489-99
pubmed: 11836274
J Endocrinol. 2002 Jul;174(1):121-5
pubmed: 12098670
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120
J Clin Endocrinol Metab. 2004 Mar;89(3):1181-7
pubmed: 15001606
J Cell Physiol. 2006 Feb;206(2):309-21
pubmed: 16021636
Clin Chem Lab Med. 2005;43(7):715-20
pubmed: 16207130
J Clin Endocrinol Metab. 2006 Apr;91(4):1210-7
pubmed: 16403820
Cardiol Rev. 2005 Nov-Dec;13(6):322-7
pubmed: 16708441
J Clin Endocrinol Metab. 2006 Dec;91(12):4930-7
pubmed: 17003097
Ann Surg. 1927 Dec;86(6):877-84
pubmed: 17865795
Stat Med. 2008 Apr 15;27(8):1133-63
pubmed: 17886233
Diabetologia. 2008 Feb;51(2):211-3
pubmed: 18094955
Arch Intern Med. 2008 Mar 24;168(6):587-92
pubmed: 18362250
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Endocrine. 2011 Feb;39(1):28-32
pubmed: 21072691
J Thyroid Res. 2011;2011:439463
pubmed: 21785689
Br Med Bull. 2011;99:39-51
pubmed: 21893493
J Diabetes Res. 2013;2013:390534
pubmed: 23671867
PLoS One. 2013 Jun 20;8(6):e66711
pubmed: 23818961
Curr Diab Rep. 2013 Dec;13(6):814-23
pubmed: 24037313
PLoS One. 2013 Sep 16;8(9):e75789
pubmed: 24066186
Eur Thyroid J. 2013 Jun;2(2):83-92
pubmed: 24783045
Diabetes Care. 2015 Sep;38(9):1657-64
pubmed: 26070591
PLoS One. 2015 Aug 13;10(8):e0135233
pubmed: 26270348
Diabetes Care. 2015 Oct;38(10):1945-51
pubmed: 26307608
J Clin Endocrinol Metab. 2016 Feb;101(2):669-77
pubmed: 26583583
Obes Rev. 2016 Mar;17(3):262-75
pubmed: 26663309
Ann Transl Med. 2016 Jan;4(1):9
pubmed: 26855945
Korean J Intern Med. 2016 Jul;31(4):703-11
pubmed: 27271351
Endocrine. 2017 Jan;55(1):179-185
pubmed: 27605039
BMC Med. 2016 Sep 30;14(1):150
pubmed: 27686165
Thyroid. 2017 Jan;27(1):29-38
pubmed: 27809684
J Clin Endocrinol Metab. 2017 Feb 1;102(2):434-442
pubmed: 27906594
Endocrine. 2017 Mar;55(3):944-953
pubmed: 28042645
Endocrinol Metab (Seoul). 2017 Mar;32(1):106-114
pubmed: 28116874
J Clin Endocrinol Metab. 2017 Jun 1;102(6):1960-1970
pubmed: 28323940
Nutr Metab Cardiovasc Dis. 2017 May;27(5):396-406
pubmed: 28416099
Am J Physiol. 1985 May;248(5 Pt 1):E593-601
pubmed: 3887944

Auteurs

T I de Vries (TI)

Department of Vascular Medicine, University Medical Center Utrecht, P.O. Box 85500, 3508 GA, Utrecht, The Netherlands.

L J Kappelle (LJ)

Department of Neurology, University Medical Center Utrecht, Utrecht, The Netherlands.

Y van der Graaf (Y)

Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.

H W de Valk (HW)

Department of Internal Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.

G J de Borst (GJ)

Department of Vascular Surgery, University Medical Center Utrecht, Utrecht, The Netherlands.

H M Nathoe (HM)

Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands.

F L J Visseren (FLJ)

Department of Vascular Medicine, University Medical Center Utrecht, P.O. Box 85500, 3508 GA, Utrecht, The Netherlands.

Jan Westerink (J)

Department of Vascular Medicine, University Medical Center Utrecht, P.O. Box 85500, 3508 GA, Utrecht, The Netherlands. J.Westerink-3@umcutrecht.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH